Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk

NCT07347977 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

1400

Enrollment

NETWORK

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Recurrence
Survival Analysis

Interventions

DRUG: Lidocaine (drug)

Sponsor

First Affiliated Hospital of Ningbo University

Collaborators

[object Object]
[object Object]
[object Object]